Frequency and Clinicopathological Characteristics of Presenilin 1 Gly206Ala Mutation in Puerto Rican Hispanics with Dementia

Manuscript Number: 

12-1570R1

Author(s): 
Steven E. Arnold, Jacob G. Dubroff, Jason Karlawish, Elisabeth McCarty-Wood, Mirna Negron, Jessica Nunez, John Q. Trojanowski, Vivianna Van Deerlin, Irving E. Vega, Li-San Wang, David Wolk, Sharon X. Xie

Disclosures

Steven E. Arnold

  • Consulting Fees:
    Cowan Group - Board Membership, Eli Lilly - Board Membership, Bristol Myers Squibb - Board Membership, Rush University Medical Center - Consultancy, Philadelphia District Attorney's Office - Consultancy, National Alzheimer Coordinating Center - Scientific Review Committee, Bonner Kiernan Trebach & Cociata LLP - Consultancy
    Lecture Fees:
    Harvard University, Trinitas Regional Medical Center, University of Puerto Rico, Massachusetts Alzheimer's Disease Research, Center/Memory Disorders Unit
    Grants
    • Agency: 
      University of California San Diego - ADNI
      Dates: 
      9/11/09-8/31/12
    • Agency: 
      Wyeth
      Dates: 
      2/8/10-12/31/12
    • Agency: 
      Pfizer
      Dates: 
      6/16/11-6/15/13
    • Agency: 
      Neuronetrix
      Dates: 
      3/2/11-12/31/12
    • Agency: 
      National Institute of Health
      Dates: 
      4/1/11-3/31/16
    • Agency: 
      Eli Lilly
      Dates: 
      9/7/11-9/30/13
    • Agency: 
      American Health Assistance Foundation
      Dates: 
      7/1/12-12/31/12
    • Agency: 
      University of California San Diego
      Dates: 
      11/1/11-12/31/14
    • Agency: 
      Bristol Myers Squibb
      Dates: 
      5/25/12/11/30/12

Jacob G. Dubroff

  • Lecture Fees:
    Siemens: Applied Radiology Webinar (9/25/2012)
    Grants
    • Agency: 
      Eli Lilly & Co.
      Dates: 
      7/2011-9/2012
    • Agency: 
      Pfizer/Wyeth Pharmaceutical Co.
      Dates: 
      7/2011-9/2012
    • Agency: 
      Elan/Janssen Pharmaceuticals
      Dates: 
      7/2011-9/2012
    • Agency: 
      Siemens
      Dates: 
      10/2011-11/2011

Jason Karlawish

  • Patents/Royalties
    I a a co-holder on a license for an integrated neurodegenerative disease database held at University of Pennsylvania.

Elisabeth McCarty-Wood

  • Nothing to Disclose

Mirna Negron

  • Nothing to Disclose

Jessica Nunez

  • Nothing to Disclose

John Q. Trojanowski

  • Consulting Fees:
    Dr. Trojanowski serves as an Associate Editor of Alzheimer's & Dementia.
    Patents/Royalties
    Dr. Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is co-Inventor and he received revenue from the sale of Avid to Eli Lily as co-inventor on imaging related patents submitted by the University of Pennsylvania.
    Grants
    • Agency: 
      NIH (AG 10124, AG 17586, AG-19724AG 024904, NS053488, AG029213)
      Dates: 
      to date
    • Agency: 
      Bristol Myer Squib
      Dates: 
      to date
    • Agency: 
      AstraZenica
      Dates: 
      to date
    • Agency: 
      several non-profits
      Dates: 
      to date

Vivianna Van Deerlin

  • Nothing to Disclose

Irving E. Vega

  • Nothing to Disclose

Li-San Wang

  • Nothing to Disclose

David Wolk

  • Nothing to Disclose

Sharon X. Xie

  • Consulting Fees:
    Dr. Xie serves as a consultant to Roche on a clinical trial unrelated to this study.